| Anderson, Craig |
ASPIRING, NCT04522102: Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe ()-Pilot Phase |
|
|
| Active, not recruiting | 3 | 80 | RoW | Start antiplatelet monotherapy | The George Institute for Global Health, China, University of Edinburgh, Huashan Hospital, The University of Western Australia | Intracerebral Hemorrhage | 10/23 | 10/23 | | |
| Completed | 3 | 2425 | RoW | urapidil, Intensive BP lowing | The George Institute for Global Health, China, Shanghai East Hospital, China, First Affiliated Hospital of Chengdu Medical College, China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China | Stroke, Acute, Cerebrovascular Disorders | 11/23 | 11/23 | | |
ACT-WHEN, NCT06320431: ACT-GLOBAL THROMBOLYSIS (-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 |
|
|
| Recruiting | 3 | 4000 | Canada, RoW | Tenecteplase, TNKase, Metalyse | University of Calgary, The George Institute for Global Health, Australia | Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic | 09/30 | 12/30 | | |
| Recruiting | 3 | 20000 | Canada, RoW | Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase, Conservative Blood Pressure Control, Moderate Blood Pressure Control, Intensive Blood Pressure Control, Placebo, NoNO-42, No deferoxamine mesylate and no colchicine, Deferoxamine mesylate only, Colchicine only, Both deferoxamine mesylate and colchicine | The George Institute, University of Calgary, Berry Consultants | Stroke | 09/34 | 09/34 | | |
| Recruiting | 3 | 1600 | Europe, RoW | telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, Triple Pill, Placebo | The George Institute, The University of New South Wales | Intracerebral Haemorrhage (ICH), Hypertension | 06/25 | 06/25 | | |
NCT05066620: Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial |
|
|
| Not yet recruiting | 3 | 1504 | RoW | Chinese herbal medicine FYTF-919, Chinese herbal medicine | Guangzhou University of Traditional Chinese Medicine, The George Institute | Intracerebral Hemorrhage | 12/24 | 01/25 | | |
| Recruiting | 3 | 400 | RoW | Atorvastatin, Standard Care | The George Institute, University of Sydney, Monash University, The Alfred, Universidad del Desarrollo, Chinese University of Hong Kong, Clinica Alemana de Santiago | Neurocognitive Impairment, Mild | 12/24 | 12/24 | | |
EAST, NCT06773364: Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial |
|
|
| Not yet recruiting | 3 | 2423 | NA | Levetiracetam, Guide-recommended management, The lying flat (0°) head position, The sitting-up (≥30°) head position | Shanghai East Hospital | Suspected Stroke | 12/28 | 12/29 | | |
| Suspended | 2 | 80 | RoW | TBO-309 | The George Institute, Heart Research Institute | Acute Ischemic Stroke | 02/26 | 05/26 | | |
NCT05483595: An Examination of Blinding for Chinese Herbal Oral Liquid and Matched Placebo |
|
|
| Completed | N/A | 48 | RoW | Chinese herbal medicine FYTF-919, Zhong Feng Xing Nao (ZFXN) prescription | Guangzhou University of Traditional Chinese Medicine | Placebo Evaluate | 06/23 | 06/23 | | |
NCT06427096: Effect of Healthy Family Program on Population Blood Pressure |
|
|
| Recruiting | N/A | 8000 | RoW | Multifaceted intervention | Heart Health Research Center | Blood Pressure | 02/25 | 08/25 | | |
ENCHANTED3/MT, NCT06352619: Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial |
|
|
| Recruiting | N/A | 2000 | Canada, RoW | Conservative SBP Control, Moderate SBP Control, Intensive SBP Control | The George Institute, University of Calgary, Changhai Hospital | Ischemic Stroke, Acute | 05/26 | 05/26 | | |
| Recruiting | N/A | 382 | RoW | Mechanical thrombectomy | The George Institute for Global Health, China, Changhai Hospital | Acute Ischemic Stroke | 10/24 | 01/25 | | |
| Recruiting | N/A | 7200 | Europe, US, RoW | Low-intensity monitoring strategy, Guideline recommended standard monitoring | Craig Anderson, Genentech, Inc., Johns Hopkins University, The George Institute for Global Health, Australia | Acute Ischemic Stroke Patients Receiving Reperfusion Therapy | 11/24 | 03/25 | | |
| Recruiting | N/A | 1675 | RoW | Intensive BP Control, Control of home SBP to a target of 120mmHg, Standard BP Control, Control of home SBP to a target of 135mmHg | Beijing Anzhen Hospital, Heart Health Research Center, The George Institute for Global Health, China, The George Institute for Global Health, Australia, Fukuoka University | Atrial Fibrillation, Hypertension | 06/24 | 12/25 | | |
NCT04157231: Essential Acute Stroke Care in Low Resource Settings: a Pilot studY |
|
|
| Not yet recruiting | N/A | 300 | RoW | Acute stroke care Intervention arm | The George Institute, World Heart Federation | Acute Stroke | 10/25 | 11/25 | | |
| Sanborn, Rachel E |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05275673: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer |
|
|
| Terminated | 2 | 7 | US | sapanisertib, CB-228 | Calithera Biosciences, Inc | Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation | 03/23 | 03/23 | | |
RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 2 | 160 | US | Osimertinib, Tagrisso, Ramucirumab, Cyramza | Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company | Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer | 09/25 | 10/25 | | |
NCT04364048: Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer |
|
|
| Terminated | 2 | 10 | US | Induction Durvalumab, IMFINZI, Chemotherapy, cisplatin, carboplatin, etoposide, pemetrexed, taxane, Radiation, Consolidation durvalumab | Rachel Sanborn, AstraZeneca, Providence Cancer Center, Earle A. Chiles Research Institute | Lung Cancer, Non-small Cell Carcinoma | 06/23 | 02/24 | | |
| Active, not recruiting | 2 | 68 | US, RoW | Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta® | Effector Therapeutics, Medpace, Inc., ICON plc | Non-small Cell Lung Cancer | 10/24 | 12/24 | | |
|
CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 30 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex | Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center | Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor | 01/25 | 01/26 | | |
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm |
|
|
| Recruiting | 2 | 244 | US | Pembrolizumab | Greg Durm, MD, Merck Sharp & Dohme LLC | NSCLC, Stage I | 04/26 | 04/29 | | |
| Recruiting | 2 | 160 | Europe, Canada, US, RoW | disitamab vedotin, RC48, RC48-ADC | Seagen Inc. | Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms | 05/26 | 05/28 | | |
NCT02422381: MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 1/2 | 16 | US | MK-3475, Anti-PD-1, Pembrolizumab, Gemcitabine, Gemzar | Providence Health & Services, Merck Sharp & Dohme LLC, Providence Cancer Center, Earle A. Chiles Research Institute | Carcinoma, Non-Small-Cell Lung | 01/19 | 08/24 | | |
NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 24 | US | ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro | Advaxis, Inc. | Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma | 02/22 | 02/22 | | |
| Recruiting | 1/2 | 232 | US | MK-6070, HPN328, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo | Small-Cell Lung Cancer, Neuroendocrine Carcinoma | 02/26 | 02/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients |
|
|
| Recruiting | 1/2 | 62 | US | quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ | Genprex, Inc. | Small Cell Lung Cancer Extensive Stage | 02/26 | 08/27 | | |
KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) |
|
|
| Recruiting | 1/2 | 333 | US | INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2 | Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma | 02/26 | 05/26 | | |
| Active, not recruiting | 1/2 | 344 | Europe, Canada, Japan, US, RoW | JDQ443, TNO155, tislelizumab | Novartis Pharmaceuticals | KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms | 04/26 | 04/26 | | |
NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 46 | US, RoW | GNX102 | GlycoNex, Inc. | Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm | 07/23 | 07/23 | | |
NCT05108623: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors |
|
|
| Completed | 1 | 34 | US | agenT-797, Approved ICIs | MiNK Therapeutics | Tumor, Solid | 01/24 | 01/24 | | |
NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 196 | US, RoW | IPG7236 | Nanjing Immunophage Biotech Co., Ltd | Safety Issues, Tolerability, Pharmacokinetics | 09/25 | 12/25 | | |
NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation |
|
|
| Terminated | 1 | 21 | US | BBP-398 with nivolumab | Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb | Non Small Cell Lung Cancer, Solid Tumor | 04/24 | 07/24 | | |
| Recruiting | 1 | 824 | Europe, US, RoW | sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin | Seagen Inc. | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 11/26 | 02/28 | | |
| Recruiting | 1 | 550 | Europe, US | Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1 | Agenus Inc. | Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer | 12/26 | 12/26 | | |
NCT03809624: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer |
|
|
| Terminated | 1 | 160 | US | INBRX-105 - PDL1x41BB antibody, Pembrolizumab, Keytruda | Inhibrx Biosciences, Inc | Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma | 10/24 | 10/24 | | |
| Recruiting | 1 | 275 | Europe, US | SGN-EGFRd2 | Seagen Inc. | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 07/27 | 09/28 | | |
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies |
|
|
| Recruiting | 1 | 270 | US | PRTH-101, Pembrolizumab | Incendia Therapeutics | Advanced or Metastatic Solid Tumors | 09/27 | 09/27 | | |
| Wang, Xin Shelley |
NCT03908138: RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma |
|
|
| Recruiting | 4 | 120 | RoW | RDD, RDD group, VDD, VDD group | Shandong Provincial Hospital | Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety | 12/21 | 12/22 | | |
NCT06398834: Esketamine and Butorphanol for Post-Lobectomy Pain |
|
|
| Completed | 4 | 223 | RoW | Esketamine, S-Ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, L-Ketamine, (-)-Ketamine, Butorphanol, Butorphanol Tartrate, Moradol, Stadol, Torbugesic, Apo-Butorphanol, Dolorex | Second People's Hospital of Hefei City, Tongji Hospital | Esketamine, Pain, Post-thoracotomy Pain Syndrome, Thoracic Diseases | 10/23 | 01/24 | | |
NCT04738955: Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors |
|
|
| Recruiting | 4 | 230 | RoW | Micafungin Sodium | Shandong Provincial Hospital | Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease | 01/23 | 10/23 | | |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT03328234: Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03 |
|
|
| Recruiting | 3 | 2 | RoW | SIB-IMRT, Paclitaxel, Platinum-Based Drug, Involved Field Irradiation (IFI) | Chinese Academy of Medical Sciences | IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer | 08/21 | 12/22 | | |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Terminated | 3 | 29 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 09/21 | 09/21 | | |
NCT03978364: A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC |
|
|
| Recruiting | 3 | 100 | RoW | Azacitidine combined HHT, Azacitidine+HHT, Azacitidine regimen, Azacitidine group | Shandong Provincial Hospital | Myelodysplastic Syndromes,Acute Myeloid Leukemia | 06/22 | 12/22 | | |
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 160 | RoW | Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX | Shandong Provincial Hospital | High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma | 12/23 | 12/24 | | |
NCT05097443: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies | Shandong Provincial Hospital | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma | 12/23 | 12/24 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT04821843: Neoadjuvant Treatment Modalities in Esophageal Cancer |
|
|
| Recruiting | 3 | 2000 | RoW | Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay, Surgery, Immunotherapy, 5-FU Analog based chemotherpay, Nimotuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric Juction Cancer | 12/25 | 12/25 | | |
NCT04821778: Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer |
|
|
| Recruiting | 3 | 2000 | RoW | Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy, Immunotherapy, 5-FU Analog based chemotherapy, Nimotuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect | 12/25 | 12/25 | | |
NCT05406882: The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis |
|
|
| Recruiting | 2/3 | 176 | RoW | Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules, Probiotics、Glutamine | West China Hospital | Radiation Proctitis, Probiotics, Glutamine, Gut Microbiota, Bifidobacterium | 04/24 | 09/24 | | |
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer |
|
|
| Completed | 2 | 55 | RoW | Radiotherapy, Nimotuzumab, S-1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm | 12/22 | 06/23 | | |
Rvision-001, NCT04147728: Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC |
|
|
| Recruiting | 2 | 50 | RoW | Anlotinib, Antiangiogenic agents, Stereotactic Radiosurgery | Peking University Third Hospital, Huashan Hospital, Tianjin Medical University | Stereotactic Body Radiation Therapy | 12/21 | 12/22 | | |
NCT04547452: Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC |
|
|
| Recruiting | 2 | 84 | RoW | Stereotactic body radiation therapy, SBRT, Anti-PD-1 antibody drug named Sintilimab | West China Hospital | Stage IV HCC, Immunotherapy, SBRT | 07/22 | 07/23 | | |
NCT06410651: Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
NCT06429839: Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients |
|
|
| Recruiting | 2 | 55 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
AK104-RC48 UC 01, NCT06178601: A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, AK104 | Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Urothelial Carcinoma | 09/24 | 04/26 | | |
NCT04821765: Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer |
|
|
| Recruiting | 2 | 35 | RoW | PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel, Cisplatin | Chinese Academy of Medical Sciences | Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease, Immunotherapy | 09/23 | 09/23 | | |
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty |
|
|
| Recruiting | 2 | 240 | RoW | Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight | Suzhou Alphamab Co., Ltd. | Knee Arthroplasty, Total | 12/25 | 04/26 | | |
POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 186 | RoW | Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor) | Beijing Friendship Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, BeiGene | Locally Advanced Rectal Cancer | 03/24 | 09/29 | | |
NCT06334367: Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT |
|
|
| Not yet recruiting | 2 | 40 | RoW | CD25 treatment, low-dose ATG | Wang Xin | GVHD | 03/26 | 03/26 | | |
| Recruiting | 2 | 90 | RoW | Tislelizumab (BGB-A317) with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer | 12/26 | 12/27 | | |
NCT06421376: Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy, Surgery | 12/26 | 12/27 | | |
NCT05490485: Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | Camrelizumab, cisplatin | Henan Cancer Hospital | Squamous Cell Carcinoma of the Skin | 07/24 | 07/24 | | |
NCT06637007: Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 30 | RoW | Chidamide Tablets combined with AK112, AK112 | Shanxi Province Cancer Hospital | Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone | 12/24 | 12/24 | | |
NCT06074484: A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, Disitamab Vedotin, AK104, Cadonilimab Injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital | Muscle Invasive Bladder Carcinoma | 08/24 | 08/25 | | |
NCT06642545: Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin, RC48, RC148, Albumin-bound Paclitaxone, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Cancer | 10/26 | 10/27 | | |
NCT05430737: A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer |
|
|
| Recruiting | 2 | 60 | RoW | stereotactic body radiotherapy | West China Hospital | Prostate Cancer, Stereotactic Body Radiotherapy, High-risk, Efficacy, Safety | 06/25 | 06/25 | | |
NCT06123455: Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Taurine, Sintilimab, XELOX regimen, SOX regimen, FOLFOX regimen | Tang-Du Hospital | Gastric Cancer | 07/25 | 07/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
NCT04278287: Chemoradiotherapy in Unresectable Esophageal Cancer |
|
|
| Recruiting | 1/2 | 105 | RoW | Radiotherapy, Albumin-Bound Paclitaxel, Nab-Paclitaxel, Cisplatin, platinum | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm | 12/25 | 12/26 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 218 | RoW | ABO2011 Injection, ABO2011, ABOD2011, Toripalimab | Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd | Solid Tumor, Adult | 12/26 | 12/27 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT06024915: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets |
|
|
| Not yet recruiting | 1 | 40 | RoW | TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 10/23 | 12/23 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
NCT06344936: Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 28 | RoW | HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules | Shandong Suncadia Medicine Co., Ltd. | Chronic Kidney Disease(CKD) | 07/24 | 07/24 | | |
NCT02988921: MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy |
|
|
| Recruiting | N/A | 300 | RoW | MRI and CT, Ratiotherapy, Paclitaxel, platinum-based drug | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer, Esophagogastric Junction Cancer | 01/25 | 12/26 | | |
NCT03247764: A Registration Study on Depression in Patients With Epilepsy |
|
|
| Recruiting | N/A | 320 | RoW | | Shanghai Zhongshan Hospital | Epilepsy, Depression | 12/21 | 01/22 | | |
NCT03902041: The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT |
|
|
| Not yet recruiting | N/A | 160 | RoW | Eltrombopag | Shandong Provincial Hospital | Allogeneic Hematopoietic Stem Cell Transplantation, Eltrombopag | 04/22 | 10/22 | | |
| Recruiting | N/A | 300 | RoW | Paclitaxel DCB | Beijing Hospital | Coronary Disease | 01/23 | 07/23 | | |
NCT06347965: Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy |
|
|
| Completed | N/A | 104 | RoW | Low load blood flow restriction training, Progressive resistance training group | Xin Wang | Sarcopenia, Lung Neoplasms | 11/23 | 02/24 | | |
NCT06391788: Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy |
|
|
| Recruiting | N/A | 132 | RoW | thoracoscopic Morrow surgery, modified Morrow surgery | China National Center for Cardiovascular Diseases | Cardiomyopathy, Hypertrophic Obstructive, Minimally Invasive Surgery | 02/25 | 03/25 | | |
NCT04502628: Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT |
|
|
| Recruiting | N/A | 150 | RoW | Hyperbaric oxygen therapy | Shandong Provincial Hospital | Stem Cell Transplant Complications | 07/23 | 12/24 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT04664439: Follow-up With CT-FFR in CHD Patients After DCB |
|
|
| Recruiting | N/A | 92 | RoW | CT-FFR | Beijing Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College | Coronary; Ischemic | 12/23 | 06/24 | | |
NCT05723731: Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation |
|
|
| Terminated | N/A | 106 | RoW | taVNS, Laxative Agent | Air Force Military Medical University, China | Chronic Constipation | 07/23 | 09/23 | | |
NCT05718778: Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma |
|
|
| Recruiting | N/A | 31 | RoW | Piamprimab (AK105), radiotherapy | Henan Cancer Hospital | Soft Tissue Sarcoma | 03/24 | 03/24 | | |
CLL2023, NCT05920668: Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | Orelabrutinib | Wang Xin | CLL/SLL | 07/24 | 07/25 | | |
NCT06128252: Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer |
|
|
| Recruiting | N/A | 96 | RoW | Taurine, Serplulimab, XELOX regimen, Placebo | Tang-Du Hospital | Gastric Cancer | 06/26 | 06/26 | | |
NCT05934864: Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST) |
|
|
| Recruiting | N/A | 1000 | RoW | 84-gene penal | Ruijin Hospital, West China Hospital, Shandong Provincial Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Institute and Hospital | Peripheral T Cell Lymphoma | 06/25 | 06/26 | | |
